Numab Therapeutics AG

Numab Therapeutics AG

Biotechnology Research Horgen, Zürich, Ch 66 employees IPO
Employees
66
Contacts
3
Emails
3
Phones
1

Numab Therapeutics AG Overview

Headquarters
Horgen, Zürich, Ch
Phone Number
Available in AeroLeads
Website
numab.com
Industry
Biotechnology Research
Employees
66
Founded
2011
Stock Symbol
IPO
Funding
54.9M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Numab Therapeutics AG

Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.

Numab Therapeutics AG Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
1
25.0% coverage

Numab Therapeutics AG Org Chart

Sample employees and titles
Name Title Contact
Lars-Kristian Bråten Hands-on Nasdaq Ipo Project Management
Email Phone
Piritta Felker
View
Dan Snell SVP, Research & Preclinical Development
Email
James Singleton General Counsel and Board Secretary
Email

Employees by Management Level

Individual contributor 8 profiles
Associate / junior 3 profiles
Manager 2 profiles
Director 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 6 6 2
Executive 1 1 0
Finance 1 1 0
Legal 1 1 0

Numab Therapeutics AG Tech Stack

Data / AI 2 profiles

Compare Similar Companies to Numab Therapeutics AG